Browse studies

Find your next paid study

3,226 recruiting studies matching your filters

Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosune…

Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of WashingtonNCT06442475

Observational

A Confirmatory Efficacy Trial of Engaging a Novel Sleep/Circadian Rhythm Target as Treatment for Depression in Adolescents

The overall aim of this proposal is a confirmatory efficacy trial sufficiently powered and designed to test the hypothesis that improving the relationship betw…

Depression in AdolescenceDelayed Sleep Phase

Estimated

~$10 – $750

Actual pay is set by the research site.

Children's Hospital Los AngelesNCT06139861

Phase 1

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort

This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nG…

High Grade GliomaGlioblastoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Joseph's Hospital and Medical Center, PhoenixNCT06072586

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor…

Brain MetastasesBrain Metastases, AdultMetastatic Brain Tumor+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT05559853

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) REDCap Registry

The Center for Autonomic Medicine in Pediatrics (CAMP) has collaborated with doctors from around the world to build the first International ROHHAD (Rapid-onset…

ROHHADRapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Ilya KhaytinNCT03135730

Phase 2

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with…

Neuroendocrine Tumor Grade 2Neuroendocrine Tumors

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT04339036

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-s…

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Guardant Health, Inc.NCT05059444

Phase 1

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibito…

Colorectal CancerCRCPancreatic Ductal Adenocarcinoma+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Revolution Medicines, Inc.NCT06445062

Phase 2

A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild…

Advanced Melanoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT06594991

Phase 1

A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safet…

Advanced or Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Hanmi Pharmaceutical Company LimitedNCT06234397

An Observational Study of Patients With Dermatologic Disease

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who tre…

VitiligoAtopic DermatitisAlopecia Areata+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Target PharmaSolutions, Inc.NCT07748169

Phase 2

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

This phase II trial tests the safety, side effects and best dose of BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel and how well it w…

Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT07226856